Vergosteen

Vergostin is a medication for the treatment of NS; it is used for vestibular disorders.

Indications Vergostina

It is used in people with Meniere's syndrome, which is characterized by the following symptoms:

• dizziness, which is sometimes accompanied by vomiting and nausea;
• hearing loss (development of deafness );
• tinnitus.

It is also prescribed to eliminate the manifestations of dizziness associated with the vestibular apparatus and having various etiologies.

Release form

The therapeutic agent is released in tablet form, 10 pieces per blister pack; there are 3 packs per pack.

Pharmacodynamics

The principle of the therapeutic effect of betahistine has not been fully studied. The substance potentiates vascular circulation in the inner ear area - mainly by relaxing the tense precapillary sphincters within the microcirculatory inner ear system.

It has been found that betahistine has a slight agonistic effect on H1-terminals and a strong antagonistic effect on histamine H3-terminals within the autonomic NS and CNS. At the same time, betahistine has a dose-dependent inhibitory effect on the generation of maximal potentials associated with neurons located within the vestibular nuclei (including medial and lateral ones).

The drug increases the rate of restoration of vestibular activity after performing unilateral neurectomy, simplifying and accelerating the developing vestibular compensation, which has a central character. This effect develops by potentiating the processes of regulation of histamine release together with the exchange, and then is realized by means of antagonism of H3-endings.

When all these effects are combined, the drug develops a positive medicinal effect in the case of Meniere's syndrome, as well as vertigo associated with the vestibular apparatus, which has different etiologies.

The drug potentiates the release and metabolism of histamine, blocking the activity of presynaptic H3-terminals, due to which their sensitivity is weakened. This effect on the histaminergic system explains the high efficiency of the drug in the treatment of vestibular disorders and dizziness.

Pharmacokinetics

Betahistine is completely absorbed at a high rate when taken orally. Excretion occurs in urine (90%) in the form of 2-pyridylacetic acid within 24 hours of taking the tablet. The substance is not detected in an unchanged state.

Tests using a radioactively labeled component have shown that its half-life is 3-4 hours, and its half-life in urine is 3-5 hours.

Dosing and administration

The prescribed dose is 24-48 mg of the substance per day, which should be divided into several equal doses:

• volume 8 mg – 1-2 tablets 3 times a day;
• volume 16 mg – 0.5-1 tablet 3 times a day;
• volume 24 mg – 1 tablet 2 times a day.

The portion size is selected for each patient individually, taking into account the impact it has on him.

A weakening of the signs of pathology is sometimes noted only after 2-3 weeks of therapy.

The maximum effect from using Vergostin can be achieved after taking it for several months. There is evidence that when therapy is started at the early stages of the disease, its deterioration or complete hearing loss at later stages is prevented.

[ 2 ]

Use Vergostina during pregnancy

The medication should not be prescribed during lactation or pregnancy.

Contraindications

Among the contraindications:

• the presence of severe hypersensitivity to any of the components of the drug;
• pheochromocytoma.

Side effects Vergostina

The administration of the drug may result in the occurrence of some side effects:

• gastrointestinal disorders: dyspepsia or nausea often occur. Mild gastric disorders may occur (for example, flatulence, vomiting, and gastrointestinal pain), which usually go away if the dosage of the drug is reduced or taken with food;
• dysfunction of the nervous system: headaches often develop;
• immune disorders: manifestations of intolerance, such as anaphylaxis;
• Problems related to the subcutaneous layer and epidermis: symptoms of hypersensitivity, including urticaria with rashes, Quincke's edema and itching.

[ 1 ]

Overdose

In cases of drug poisoning (use of a dose of up to 0.64 g), mild to moderate symptoms (abdominal pain, nausea, and drowsiness) were observed. In cases of intentional use of higher doses, more severe disorders (complications affecting cardiopulmonary function and seizures) developed, especially when combined with intoxication with other drugs.

Conventional supportive care is used to treat the disorder.

Interactions with other drugs

In vivo testing to investigate interactions with other medications has not been performed. In vitro testing data suggest that the drug does not inhibit cytochrome P450 enzyme activity in vivo.

In vitro data show that betahistine metabolism is inhibited by substances that inhibit the activity of the MAO element (including the B-MAO subtype, such as selegiline). Vergostin should be combined with MAOI drugs with extreme caution.

Based on the fact that betahistine is included in the group of analogues of the histamine component, when combining the drug with antihistamines, in theory, an effect on the therapeutic effectiveness of any of the indicated drugs may develop.

[ 3 ], [ 4 ]

Storage conditions

Vergostin should be kept in a place that is closed to small children. Temperature values are within the range of 25°C.

Shelf life

Vergostin can be prescribed for a period of 24 months from the date of manufacture of the therapeutic substance.

Application for children

Vergostin is not used in pediatrics (individuals under 18 years of age) because there is little information regarding drug efficacy and safety for this group of patients.

[ 5 ]

Analogues

The following drugs are considered analogues of the drug: Betaserk, Betaver, Tagista with Vesticap and Vestibo.